LAMEA Attention Deficit Hyperactivity Disorder Market 2022: Sector to Grow by 7.3% Annually Through 2028
2023-01-18
DUBLIN, Jan. 18, 2023 /PRNewswire/ -- The "LAMEA Attention Deficit Hyperactivity Disorder Market Size, Share & Industry Trends Analysis Report By Drug Type, By Demographics (Adults and Children), By Distribution Channel (Retail Pharmacy and Hospital Pharmacy), By Country and Growth Forecast, 2022 - 2028" report has been added to
ResearchAndMarkets.com's offering.
The Latin America, Middle East and Africa Attention Deficit Hyperactivity Disorder Market should witness market growth of 7.3% CAGR during the forecast period (2022-2028).
As novel treatments are released, it will be crucial to assess their cost-effectiveness to give clinicians, third-party payers, patients, and families an idea of their potential worth. In the near future, the market expansion is anticipated to be driven by extensive research studies carried out by organizations to assess the safety and efficacy of medications in patients with ADHD. Positive findings from these investigations create new business prospects.
For example, alpha-2-adrenergic agonists like guanfacine & clonidine, according to a Boston Children's Hospital study from 2021, can be helpful in reducing illness symptoms in children.
Additionally, it is shown that these drugs have fewer adverse side effects than other stimulants such as amphetamines (Adderall, Vyvanse), methylphenidate (Ritalin, Concerta), and caffeine, which are frequently used as initial treatments for the disorder. Therefore, the expansion of essential players' efforts to promote their products is creating new economic opportunities.
Several studies have established a high variation in the prevalence of ADHD in Brazil. Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood. This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation. Similarly, in the Middle East region, the prevalence of ADHD was assessed based on the DSM-IV guidelines in Egypt, Palestine, Saudi Arabia, Tunisia, Oman, Qatar, Lebanon, Tunisia, and Iraq.
The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028. The Argentina market is showcasing a CAGR of 7.9% during (2022-2028). Additionally, The UAE market would register a CAGR of 7% during (2022-2028).
Scope of the Study
By Drug Type
Stimulants
Amphetamine
Non-stimulants
Clonidine
Others
By Demographics
Adults
Children
By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
By Country
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
Lupin LimitedLupin Limited
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Strategies deployed in Attention Deficit Hyperactivity Disorder Market
Chapter 4. LAMEA Attention Deficit Hyperactivity Disorder Market by Drug Type
Chapter 5. LAMEA Attention Deficit Hyperactivity Disorder Market by Demographics
Chapter 6. LAMEA Attention Deficit Hyperactivity Disorder Market by Distribution Channel
Chapter 7. LAMEA Attention Deficit Hyperactivity Disorder Market by Country
Chapter 8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/agko95
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。